Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Saad F, et al. Among authors: efstathiou e. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.
Ranganathan S, Riveros C, Xu J, Hu S, Geng M, Huang E, Melchiode Z, Zhang J, Efstathiou E, Chan KS, Wallis CJD, Sonpavde G, Satkunasivam R. Ranganathan S, et al. Among authors: efstathiou e. Urol Oncol. 2024 May 18:S1078-1439(24)00428-9. doi: 10.1016/j.urolonc.2024.04.006. Online ahead of print. Urol Oncol. 2024. PMID: 38763801
Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents.
Efstathiou E, Merseburger A, Liew A, Kurtyka K, Panda O, Dalechek D, Heerdegen ACS, Jain R, De Solda F, McCarthy SA, Brookman-May SD, Mundle SD, Yu Ko W, Krabbe LM. Efstathiou E, et al. ESMO Open. 2024 May;9(5):103007. doi: 10.1016/j.esmoop.2024.103007. Epub 2024 May 14. ESMO Open. 2024. PMID: 38744101 Free PMC article. Review.
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.
Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Gentile E, et al. Among authors: efstathiou e. Cancer Res Commun. 2023 Dec 13;3(12):2531-2543. doi: 10.1158/2767-9764.CRC-23-0362. Cancer Res Commun. 2023. PMID: 37930121 Free PMC article.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, Giorgi U, Shore ND, Saad F. Hussain M, et al. Among authors: efstathiou e. Future Oncol. 2023 Sep;19(29):1953-1960. doi: 10.2217/fon-2023-0135. Epub 2023 Aug 10. Future Oncol. 2023. PMID: 37585665 Free article. Review.
Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
Faustini SE, Cook A, Hill H, Al-Taei S, Heaney J, Efstathiou E, Tanner C, Townsend N, Ahmed Z, Dinally M, Hoque M, Goodall M, Stamataki Z, Plant T, Chapple I, Cunningham AF; PITCH consortium; Drayson MT, Shields AM, Richter AG. Faustini SE, et al. Among authors: efstathiou e. J Infect. 2023 Oct;87(4):328-335. doi: 10.1016/j.jinf.2023.07.018. Epub 2023 Aug 3. J Infect. 2023. PMID: 37543310 Free article.
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Chi KN, et al. Among authors: efstathiou e. Ann Oncol. 2023 Sep;34(9):772-782. doi: 10.1016/j.annonc.2023.06.009. Epub 2023 Jul 1. Ann Oncol. 2023. PMID: 37399894 Free article. Clinical Trial.
228 results